Eloxx Pharmaceuticals, Inc.

NasdaqCM:ELOX Stock Report

Market Cap: US$63.6m

Eloxx Pharmaceuticals Management

Management criteria checks 2/4

Eloxx Pharmaceuticals' CEO is Sumit Aggarwal, appointed in Apr 2021, has a tenure of 5.42 years. total yearly compensation is $1.76M, comprised of 35.9% salary and 64.1% bonuses, including company stock and options. directly owns 3.77% of the company’s shares, worth $2.40M. The average tenure of the management team and the board of directors is 5.4 years and 8.3 years respectively.

Key information

Sumit Aggarwal

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage35.95%
CEO tenure5.4yrs
CEO ownership3.8%
Management average tenure5.4yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 14

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX), a company focused on rare diseases, announced Wednesday that its lead candidate, ELX-02 in combination with ivacaftor, did not achieve efficacy endpoints in a Phase 2 trial involving certain patients with cystic fibrosis (CF). ELOX shares are currently on hold for trading. The study evaluated ELX-02 as monotherapy in combination with ivacaftor in Class 1 CF patients with at least one nonsense genetic mutation. According to topline data, the drug was well tolerated with no treatment-related serious adverse events. However, the trial did not achieve statistical significance for efficacy endpoints, including changes in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1) from the baseline. Given the safety and signs of clinical activity, ELOX, as previously announced, plans to start a proof-of-concept trial for ELX-02 later this year, targeting patients with the rare kidney disease, Alport syndrome.
Seeking Alpha • Aug 15

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals press release (NASDAQ:ELOX): Q2 GAAP EPS of -$0.12 in-line. As of June 30, 2022, Eloxx had unrestricted cash and cash equivalents of $30.0M. "As of June 30, 2022, the Company was in compliance with all debt covenants. If our lender does not accelerate our debt upon our failure to comply with the minimum cash covenant, we expect our current cash position will be sufficient to fund our operations into the fourth quarter of 2023," the company statement.
Analysis Article • Sep 09

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 17

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The big shareholder groups in Eloxx Pharmaceuticals, Inc. ( NASDAQ:ELOX ) have power over the company. Institutions...

CEO Compensation Analysis

How has Sumit Aggarwal's remuneration changed compared to Eloxx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$11m

Mar 31 2026n/an/a

-US$8m

Dec 31 2025US$2mUS$631k

-US$6m

Dec 31 2024US$1mUS$631k

-US$3m

Dec 31 2023US$1mUS$609k

-US$17m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$575k

-US$36m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$6mUS$408k

-US$67m

Compensation vs Market: Sumit's total compensation ($USD1.76M) is above average for companies of similar size in the US market ($USD652.98K).

Compensation vs Earnings: Sumit's compensation has increased whilst the company is unprofitable.

CEO

Sumit Aggarwal (53 yo)

5.4yrs
Tenure
US$1,755,079
Compensation

Mr. Sumit Aggarwal, MBA is Chief Executive officer of Endolytix Technology, Inc. Mr. Aggarwal serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He joined as President and Chief Exec...

Leadership Team

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President5.4yrsUS$1.76m3.77%
$ 2.4m
Daniel Geffken
Interim Chief Financial Officer5.4yrsUS$450.44k0.0028%
$ 1.8k
John Woolford
VP & Head of Corporate Developmentno datano datano data
Ali Hariri
Chief Medical Officer4.8yrsno datano data
Roger Clark
VP & Head of Discovery Sciencesno datano datano data
Teji Singh
VP & Head of Clinical Developmentno datano datano data
5.4yrs
Average Tenure

Experienced Management: ELOX's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President5.4yrsUS$1.76m3.77%
$ 2.4m
Steven Rubin
Independent Director12.3yrsUS$71.19k0.034%
$ 21.7k
Alan Walts
Independent Chairman5.4yrsUS$100.61k0.036%
$ 23.0k
Patrick Flume
Member of Medical Advisory Boardno datano datano data
Timor Baasov
Member of Scientific Advisory Boardno datano datano data
Noreen Henig
Member of Medical Advisory Boardno datano datano data
David Bedwell
Member of Scientific Advisory Board8.3yrsno datano data
Rachel Green
Member of Scientific Advisory Board8.3yrsno datano data
Sudhir Kumar
Member of Scientific Advisory Board8.3yrsno datano data
Lynne Maquat
Member of Scientific Advisory Board8.3yrsno datano data
Donald Vandevanter
Member of Medical Advisory Boardno datano datano data
Christiane De Boeck
Member of Medical Advisory Boardno datano datano data
8.3yrs
Average Tenure
63.5yo
Average Age

Experienced Board: ELOX's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 00:10
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yun ZhongBrean Capital Historical (Janney Montgomery)
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity